Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for lymphoma and blood disorders
This trial tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy helps treat lymphomas that have come back or not responded, as well as two related blood disorders (CCUS and CMML). The goal is to see if the vitamin C makes the chemo work better.
Mankato, MinnesotaAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Duarte, CaliforniaAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Birmingham, AlabamaAges Any age - NCT03238378Recruiting
Radiation boost plus warming for recurrent head and neck tumors
This trial tests a “salvage” treatment that combines targeted radiation (brachytherapy) with controlled body warming (hyperthermia) for head and neck cancer that has come back. It may help by better shrinking tumors while fitting the treatment to the tumor’s exact location.
ErlangenAges 18 years+ - NCT04288999RecruitingPhase 3
Surgery plus chemo versus chemo-radiation then surgery for recurrent rectal cancer
This study compares two treatment plans for locally recurrent rectal cancer: (1) surgery plus chemo, or (2) chemo plus radiation first, then surgery, followed by chemo. It aims to see which approach works better in controlling the cancer and helping patients recover.
ChibaAges 20–80 - NCT04695782RecruitingPhase 2
Proton radiation for recurrent rectal cancer in the pelvis
This trial studies “pencil beam” proton radiation for rectal cancer that has come back in the pelvis after you already had radiation. It aims to control the recurrence while trying to limit harm to nearby organs.
AarhusAges 18 years+ - NCT04376866RecruitingPhase 3
Immunotherapy for repeat nasopharyngeal cancer after it returns
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
Nanning, GuangxiAges 18–65 - NCT05055635RecruitingPhase 2
Proton radiation for anal cancer that came back after prior treatment
This trial studies a focused type of proton radiation (“pencil beam”) to treat anal cancer that has returned after you previously had radiation. It may help by aiming treatment more precisely and giving another chance at cure when doctors think it can still be treated.
Aarhus N, AarhusAges 18 years+ - NCT04991948RecruitingPhase 1
Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Jacksonville, FloridaAges 18 years+ - NCT03983226RecruitingPhase 2
Surgery plus niraparib for returning ovarian cancer
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05455918RecruitingPhase 2
Chemo with paclitaxel, ifosfamide, and cisplatin for high-risk germ cell tumors
This Phase 2 trial tests a specific chemotherapy combination (paclitaxel, ifosfamide, and cisplatin) for children and teens with newly diagnosed, high-risk germ cell tumors. It aims to improve outcomes by treating cancer cells with a stronger chemo plan.
SeoulAges 1–20 - NCT05553652Recruiting
A probiotic test for repeat bladder infections
This trial studies ASTARTE™, a probiotic, to see if it can reduce repeat urinary tract infections (UTIs). It may help people who get UTIs often by testing whether the supplement lowers how frequently they come back.
Hvidovre, CopenhagenAges 18–40 - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT03621904Recruiting
Predicting response to hormone treatment in endometrial cancer
This study looks at whether biopsy test results can help predict how well hormone therapy will work for advanced or recurrent endometrial cancer. It may help doctors choose the most effective hormonal treatment sooner.
NijmegenAges 18–110 - NCT05354596Recruiting
SBRT radiation trial for central lung tumors
This trial studies a focused, high-dose radiation treatment called SBRT for lung tumors that are hard to operate on, including very central tumors near major airways or organs. It may help people control tumor growth while limiting radiation exposure to nearby critical structures.
AalborgAges 18 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05595603RecruitingPhase 2
Zoledronic acid in bone cement after tumor scraping
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
HangzhouAges Any age - NCT05754853RecruitingPhase 3
MRG002 antibody compared with standard chemo for HER2 bladder cancer
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT04647097Recruiting
Quit smoking and alcohol to prevent pancreatitis coming back
This trial is studying whether stopping alcohol and quitting smoking can help keep acute pancreatitis from returning. It’s for people whose pancreatitis happened because of alcohol, and who smoke every day.
PécsAges 18–80 - NCT05367089RecruitingPhase 3
Honey treatment for frequent vaginal yeast infections
This Phase 3 study tests a medical-grade honey product (L-Mesitran) to reduce symptoms from recurrent vaginal yeast infections. If you have frequent episodes, the honey treatment may help lower symptom flare-ups compared with usual care.
HeerlenAges 18 years+ - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.